These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9817189)

  • 1. Renal function in noninsulin-dependent diabetes mellitus patients treated with angiotensin-converting enzyme inhibitors and calcium channel blockers.
    Nosadini R; Brocco E; Saller A; Cernigoi AM; Abaterusso C; Bortoloso E; Dalla Vestra M; Maioli M; Piarulli F; Fioretto P
    J Hypertens Suppl; 1998 Sep; 16(4):S27-32. PubMed ID: 9817189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.
    Velussi M; Brocco E; Frigato F; Zolli M; Muollo B; Maioli M; Carraro A; Tonolo G; Fresu P; Cernigoi AM; Fioretto P; Nosadini R
    Diabetes; 1996 Feb; 45(2):216-22. PubMed ID: 8549868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
    O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
    J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
    Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
    Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of antihypertensive agents on proteinuria and renal function.
    Maki DD; Ma JZ; Louis TA; Kasiske BL
    Arch Intern Med; 1995 May; 155(10):1073-80. PubMed ID: 7748051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
    Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
    J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension and renal complications in type 2 diabetes.
    Nosadini R
    Semin Vasc Med; 2002 Feb; 2(1):109-19. PubMed ID: 16222601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
    Kanno Y; Okada H; Saruta T; Suzuki H
    Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
    Coyle JD; Gardner SF; White CM
    Ann Pharmacother; 2004 Oct; 38(10):1731-8. PubMed ID: 15353571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiorenal protection in diabetes.
    Pickering TG
    Heart Dis; 2000; 2(2):S18-22. PubMed ID: 11728259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.